Parkinson’s iPS-Cell Therapy Enters Japan’s Public Insurance: the ¥55.3 Million “Amchepry”
Japan has added Amchepry (raguneprocel) — the world’s first commercialized iPS cell–derived product — to public insurance at ~¥55.3 million. What the Sumitomo Pharma / Kyoto University Parkinson’s therapy is, and what its conditional approval means.
